Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems

Journal of Pharmaceutical Sciences

Volumn 102, Issue 11, 2013, Pages 3867-3882

  Narang, Ajit S ^a   Chang, Rong Kun ^b   Hussain, Munir A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Liposomes; Micelle; Microemulsion; Nano milling; Nanoparticles; Nanotechnology; Polymeric drug carrier; Polymeric drug delivery systems; Polymeric drugs

Indexed keywords

ANTHELIOS; ANTIBODY CONJUGATE; APREPITANT; CYCLOSPORIN A; DOCETAXEL; DODECYL SULFATE SODIUM; EMLA; ESTRADIOL; FENOFIBRATE; GELATIN; GORTOVASE; HELIOBLOCK; HYDROXYPROPYLMETHYLCELLULOSE; LIPOSOME; MACROGOL; MEGESTROL ACETATE; NANOPARTICLE; NEW DRUG; NON PRESCRIPTION DRUG; PACLITAXEL; PALIPERIDONE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYMER; RAPAMYCIN; RITONAVIR; SAQUINAVIR; STABILIZING AGENT; SUNSCREEN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SURFACTANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER OIL CREAM;

ADSORPTION; AREA UNDER THE CURVE; BIOCOMPATIBILITY; CAPSULE ENDOSCOPE; CHEMICAL MODIFICATION; COLLOID; COMMERCIAL PHENOMENA; DENSITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG INDUSTRY; DRUG PENETRATION; DRUG RETENTION; DRUG STABILITY; EMULSION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MICELLE; MICROEMULSION; NANOPARTICULATE DRUG DELIVERY SYSTEM; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; NOTE; PARTICLE SIZE; PATENT; POLYMERIZATION; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SILVER DRESSING; SOLVENT EFFECT; SURFACE CHARGE; SURFACE PROPERTY; SUSPENSION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

LIPOSOMES; MICELLE; MICROEMULSION; NANO MILLING; NANOPARTICLES; NANOTECHNOLOGY; POLYMERIC DRUG CARRIER; POLYMERIC DRUG DELIVERY SYSTEMS; POLYMERIC DRUGS;

DRUG APPROVAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; MICELLES; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84885838236     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23691     Document Type: Note

References (71)

1. Berger M. 2008. Ethical aspects of nanotechnology in medicine. Accessed January 15, 2013, at: http://www.nanowerk.com/spotlight/spotid=3938.php.
2. Fattal E, Vauthier C. 2006. Drug delivery: Nanoparticles. In Encyclopedia of pharmaceutical technology; Swarbrick J, Boylan JC, Eds. 3rd ed. New York City, New York: Informa Healthcare.
3. Narang AS, Mahato RI. 2010. Targeted delivery of small and macromolecular drugs. Boca Raton, Florida: CRC Press.
4. Panakanti R, Narang AS. 2012. Impact of excipient interactions on drug bioavailability from solid dosage forms. Pharm Res 29(10):2639-2659.
5. Yu LX. 1999. An integrated model for determining causes of poor oral drug absorption. Pharm Res 16(12):1883-1887.
6. Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, Yamashita S. 2008. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res 25(10):2334-2344.
7. Kerkhof NJ. 2001. Patent US34606.
8. Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. 2008. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm 359(1-2):211-219.
9. Zhu WZ, Wang JX, Shao L, Zhang HX, Zhang QX, Chen JF. 2010. Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor. Int J Pharm 395(1-2):260-265.
10. Wang J-X, Zhang Q-X, Zhou Y, Shao L, Chen J-F. 2010. Microfluidic synthesis of amorphous cefuroxime axetil nanoparticles with size-dependent and enhanced dissolution rate. Chem Eng J (Amsterdam, Netherlands) 162(2):844-851.
11. Varshosaz J, Hassanzadeh F, Mahmoudzadeh M, Sadeghi A. 2009. Preparation of cefuroxime axetil nanoparticles by rapid expansion of supercritical fluid technology. Powder Technol 189(1):97-102.
12. Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ. 2008. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69(2):454-465.
13. Overhoff KA, Engstrom JD, Chen B, Scherzer BD, Milner TE, Johnston KP, Williams 3rd RO. 2007. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm Biopharm 65(1):57-67.
14. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams 3rd RO. 2008. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 361(1-2):177-188.
15. Yang W, Johnston KP, Williams 3rd RO. 2010. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 75(1):33-41.
16. Yu L, Li C, Le Y, Chen J-F, Zou H. 2011. Stabilized amorphous glibenclamide nanoparticles by high-gravity technique. Mater Chem Phys 130(1-2):361-366.
17. Dhumal RS, Biradar SV, Yamamura S, Paradkar AR, York P. 2008. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Eur J Pharm Biopharm 70(1):109-115.
18. Chinea VI, Kane KM, Ruiz O. 2005. Patent US189585.
19. Mahato RI, Narang AS. 2012. Pharmaceutical dosage forms and drug delivery. 2nd ed. Boca Raton, Florida: CRC Press, p 472.
20. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5(6):1003-1019.
21. Yin SX, Franchini M, Chen J, Hsieh A, Jen S, Lee T, Hussain M, Smith R. 2005. Bioavailability enhancement of a COX-2 inhibitor, BMS-347070, from a nanocrystalline dispersion prepared by spray-drying. J Pharm Sci 94(7):1598-1607.
22. Qian F, Tao J, Desikan S, Hussain M, Smith RL. 2007. Mechanistic investigation of Pluronic based nano-crystalline drug-polymer solid dispersions. Pharm Res 24(8):1551-1560.
23. Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M. 2012. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharm Res 29(10):2765-2776.
24. Muller RH, Bohm BHL. 1998. Nanosuspesions. In Emulsions and nanosuspensions for the formulation of poorly soluble drugs; Muller RH, Benita S, Bohm BHL, Eds. Stuttgart, Germany: Medpharm Scientific Publishers, pp 149-174.
25. Gao L, Zhang D, Chen M. 2008. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanoparticle Res 10(5):845-862.
26. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18(2):113-120.
27. Patravale VB, Date AA, Kulkarni RM. 2004. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol 56(7):827-840.
28. Narang AS, Desai D, Badawy S. 2012. Impact of excipient interactions on solid dosage form stability. Pharm Res 29(10):2660-2683.
29. Narang AS, Desai D, Badawy S. 2012. Physicochemical interactions in solid dosage forms. Pharm Res 29(10):2635-2638.
30. Nanomaterials Technology. 2011. High Gravity Controlled Precipitation (HGCP) technology. Accessed January 15, 2013, at: http://www.nanomt.com/tec.asp.
31. Microfuidics Inc. 2011. PureNano Continuous Crystallizer: A breakthrough in crystallization technology enables continuous manufacturing of non-soluble drug suspensions. Accessed January 15, 2013, at: http://www.microfluidicscorp.com/images/stories/PureNano_Crystallizer.pdf.
32. Gordon MS. 1998. Patent US23905.
33. Narang AS, Delmarre D, Gao D. 2007. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 345(1-2):9-25.
34. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45(1):89-121.
35. Gibaud S, Attivi D. 2012. Microemulsions for oral administration and their therapeutic applications. Expert Opin Drug Deliv 9(8):937-951.
36. Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688-701.
37. Silverstein SB, Rodgers GM. 2004. Parenteral iron therapy options. Am J Hematol 76(1):74-78.
38. Petrak K. 1986. Polyelectrolyte complexes in biomedical applications. J Bioactive Compat Polym 1(2):202-219.
39. Krone V, Magerstaedt M, Walch A, Groener A, Hoffmann D. 1991. Patent 1991-106495454044.
40. Valery C, Pouget E, Pandit A, Verbavatz JM, Bordes L, Boisde I, Cherif-Cheikh R, Artzner F, Paternostre M. 2008. Molecular origin of the self-assembly of lanreotide into nanotubes: A mutational approach. Biophys J 94(5):1782-1795.
41. Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O. 2009. Self-emulsifying drug delivery systems (SEDDS): Formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst 26(5):427-521.
42. Gursoy RN, Benita S. 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58(3):173-182.
43. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. 1994. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 106(1):15-23.
44. Tarr BD, Yalkowsky SH. 1989. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res 6(1):40-43.
45. Xia D, Cui F, Piao H, Cun D, Jiang Y, Ouyang M, Quan P. 2010. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res 27(9):1965-1976.
46. Zhang L, Pornpattananangku D, Hu CM, Huang CM. 2010. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 17(6):585-594.
47. Zhang Z, Lai Y, Yu L, Ding J. 2010. Effects of immobilizing sites of RGD peptides in amphiphilic block copolymers on efficacy of cell adhesion. Biomaterials 31(31):7873-7882.
48. Alipour M, Halwani M, Omri A, Suntres ZE. 2008. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 355(1-2):293-298.
49. Narang AS, Varia S. 2011. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 63(8):640-658.
50. Narang AS, Desai DD. 2009. Anticancer drug development: Unique aspects of pharmaceutical development. In Pharmaceutical perspectives of cancer therapeutics; Mahato RI, Lu Y, Eds. New York City, New York: AAPS-Springer Publishing Program.
51. McDonald DM, Choyke PL. 2003. Imaging of angiogenesis: From microscope to clinic. Nat Med 9(6):713-725.
52. Lammers T, Hennink WE, Storm G. 2008. Tumour-targeted nanomedicines: Principles and practice. British J Cancer 99(3):392-397.
53. Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE. 2004. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: An open-label, single-dose study. Cancer Chemotherapy and Pharmacol 54(6):514-524.
54. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J. 1999. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Res Campaign Phase I/II Committee. Clin Cancer Res 5(1):83-94.
55. Torchilin V. 2010. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63(3):131-135.
56. Danhier F, Feron O, Preat V. 2010. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135-146.
57. Kuai R, Yuan W, Qin Y, Chen H, Tang J, Yuan M, Zhang Z, He Q. 2010. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm 7(5):1816-1826.
58. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. 2000. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89(5):1037-1047.
59. Landsiedel R, Fabian E, Ma-Hock L, van Ravenzwaay B, Wohlleben W, Wiench K, Oesch F. 2012. Toxico-/biokinetics of nanomaterials. Arch Toxicol 86(7):1021-1060.
60. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, Linse S. 2007. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104(7):2050-2055.
61. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. 2009. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61(6):428-437.
62. Bhatia I, Malik R. 2003. Patent WO 2003047497.
63. Florence AT. 2005. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov Today Technol 2(1):75-82.
64. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. 1996. Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res 13(12):1838-1845.
65. Jani P, Halbert GW, Langridge J, Florence AT. 1990. Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol 42(12):821-826.
66. Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. 2007. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 49(3):217-229.
67. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. 2002. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20(6):1668-1676.
68. Bundgaard M. 1980. Transport pathways in capillaries-in search of pores. Annu Rev Physiol 42:325-336.
69. Simionescu N, Simionescu M, Palade GE. 1978. Open junctions in the endothelium of the postcapillary venules of the diaphragm. J Cell Biol 79(1):27-44.
70. Seymour LW. 1992. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9(2):135-187.
71. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, Bianco A, Kostarelos K. 2006. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci USA 103(9):3357-3362.